Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue

Issues

Thrombophilia screening – at the right time, for the right patient, with a good reason

1Department of Vascular Diseases, University Medical Centre, Ljubljana, Slovenia

Corresponding author: Prof. Mojca Stegnar, PhD, Department of Vascular Diseases, University Medical Centre Ljubljana, 1525 Ljubljana, Slovenia Phone: +386 1 522 8032, Fax: +386 1 522 8070

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 48, Pages S105–S113, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2010.367, November 2010

Publication History

Received:
2010-05-19
Accepted:
2010-07-23
Published Online:
2010-11-06

Abstract

Thrombophilia can be identified in about half of all patients presenting with venous thromboembolism (VTE). Thrombophilia screening for various indications has increased tremendously, but whether the results of such tests help in the clinical management of patients is uncertain. Here, current recommendations for thrombophilia screening in selected groups of patients, and considerations whether other high-risk subjects should be tested are reviewed. The methods for determination of the most common thrombophilic defects (antithrombin, protein C, protein S deficiencies, Factor V Leiden and prothrombin G20210A) associated with strong to moderate risk of VTE are described, indicating the timing and location of thrombophilia screening. Circumstances when a positive result of thrombophilia screening helps clinicians decide if adjustments of the anticoagulant regime are needed are discussed. Finally, psychological, social and ethical dilemmas associated with thrombophilia screening are indicated.

Clin Chem Lab Med 2010;48:S105–13.

Keywords: pregnancy complications; screening; thromboembolism; thrombophilia

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Jelena Bogdanović Pristov, Dragana Maglić, Miloš Opačić, Vesna Mandić, Željko Miković, Mihajlo Spasić, and Ivan Spasojević
Thrombosis Research, 2012, Volume 130, Number 5, Page 826
[2]
Sun Young Cho, Tae Sung Park, Hee Joo Lee, Woo-In Lee, and Jin-Tae Suh
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 11

Comments (0)

Please log in or register to comment.